Literature DB >> 24550338

Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.

Farah Babakhani1, Jaime Seddon, Pamela Sears.   

Abstract

Fidaxomicin (FDX) is a narrow-spectrum antibiotic for the treatment of Clostridium difficile-associated diarrhea. While FDX and rifamycins share the same target (RNA polymerase), FDX exhibits a unique mode of action distinct from that of rifamycins. In comparative microbiological studies with C. difficile, FDX interacted synergistically with rifamycins, demonstrated a lower propensity for the development of resistance to rifamycins, and exhibited no cross-resistance with rifamycins. These results highlight differences in the mechanisms of action of FDX and rifamycins.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24550338      PMCID： PMC3993244          DOI： 10.1128/AAC.02572-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  In vitro activities of OPT-80 and comparator drugs against intestinal bacteria.

Authors:  Sydney M Finegold; Denise Molitoris; Marja-Liisa Vaisanen; Yuli Song; Chengxu Liu; Mauricio Bolaños
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.

Authors:  Kim L Credito; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

3.  A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection.

Authors:  Kevin W Garey; Shashank S Ghantoji; Dhara N Shah; Musarat Habib; Vaneet Arora; Zhi-Dong Jiang; Herbert L DuPont
Journal:  J Antimicrob Chemother       Date:  2011-09-21       Impact factor: 5.790

4.  In vitro activity and fecal concentration of rifaximin after oral administration.

Authors:  Z D Jiang; S Ke; E Palazzini; L Riopel; H Dupont
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

5.  Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance.

Authors:  Mark A Miller; Ruth Blanchette; Patrizia Spigaglia; Fabrizio Barbanti; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2011-10-12       Impact factor: 5.948

6.  Fidaxomicin inhibits toxin production in Clostridium difficile.

Authors:  Farah Babakhani; Laurent Bouillaut; Pamela Sears; Carlee Sims; Abraham Gomez; Abraham L Sonenshein
Journal:  J Antimicrob Chemother       Date:  2012-12-02       Impact factor: 5.790

7.  Fidaxomicin inhibits spore production in Clostridium difficile.

Authors:  Farah Babakhani; Laurent Bouillaut; Abraham Gomez; Pamela Sears; Ly Nguyen; Abraham L Sonenshein
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

8.  Antimicrobial activities of fidaxomicin.

Authors:  Ellie J C Goldstein; Farah Babakhani; Diane M Citron
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

9.  Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis.

Authors:  Irina Artsimovitch; Jaime Seddon; Pamela Sears
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

10.  Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.

Authors:  Pamela Sears; Derrick W Crook; Thomas J Louie; Mark A Miller; Karl Weiss
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079
View more
  12 in total

Review 1.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

2.  Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile.

Authors:  Xinyun Cao; Hande Boyaci; James Chen; Yu Bao; Robert Landick; Elizabeth A Campbell
Journal:  Nature       Date:  2022-04-06       Impact factor: 69.504

Review 3.  Mechanisms and impact of antimicrobial resistance in Clostridioides difficile.

Authors:  Chetna Dureja; Abiola O Olaitan; Julian G Hurdle
Journal:  Curr Opin Microbiol       Date:  2022-01-22       Impact factor: 7.584

Review 4.  Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.

Authors:  Jennifer A Leeds
Journal:  Cold Spring Harb Perspect Med       Date:  2016-02-01       Impact factor: 6.915

5.  Antibiotic Treatments for Clostridium difficile Infection Are Associated with Distinct Bacterial and Fungal Community Structures.

Authors:  Regina Lamendella; Justin R Wright; Jada Hackman; Christopher McLimans; David R Toole; William Bernard Rubio; Rebecca Drucker; Hoi Tong Wong; Kate Sabey; John P Hegarty; David B Stewart
Journal:  mSphere       Date:  2018-01-10       Impact factor: 4.389

6.  Semisynthetic Analogs of the Antibiotic Fidaxomicin-Design, Synthesis, and Biological Evaluation.

Authors:  Andrea Dorst; Regina Berg; Christoph G W Gertzen; Daniel Schäfle; Katja Zerbe; Myriam Gwerder; Simon D Schnell; Peter Sander; Holger Gohlke; Karl Gademann
Journal:  ACS Med Chem Lett       Date:  2020-10-14       Impact factor: 4.345

Review 7.  Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection.

Authors:  Simon D Baines; Mark H Wilcox
Journal:  Antibiotics (Basel)       Date:  2015-07-10

Review 8.  Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection.

Authors:  George G Zhanel; Andrew J Walkty; James A Karlowsky
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Nov-Dec       Impact factor: 2.471

9.  Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes.

Authors:  Christine Lee; Thomas J Louie; Karl Weiss; Louis Valiquette; Marvin Gerson; Wendy Arnott; Sherwood L Gorbach
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-05-24       Impact factor: 2.471

10.  Antimicrobial susceptibility and molecular characterisation using whole-genome sequencing of Clostridioides difficile collected in 82 hospitals in Japan between 2014 and 2016.

Authors:  Kotaro Aoki; Shinobu Takeda; Takashi Miki; Yoshikazu Ishii; Kazuhiro Tateda
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.